Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
WHO classification of haematolymphoid tumours
Gaillard, F., Weerakkody, Y., & Sharma, R. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,776
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512 · cited 5×
“They suggest to focus on kinase inhibitors of the IRAK4 pathway as potentially specific therapeutic regimen, in order to ultimately pave the way for a personalized medicine approach also in PCNSL. Acknowledgments The excellent technical assistance of Hatice Önder is appreciated.”
InfluentialDeckert, M., Engert, A., Brück, W., Ferreri, A. J. M., Finke, J., Illerhaus, G., Klapper, W., Korfel, A., Küppers, R., Maarouf, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.169 · Cited by 190 · cited 1×
“Although being a rare disease, the incidence of PCNSL has significantly raised in the last decades [3, 4], however, a specific standard therapeutic regimen is still a matter of debate [2].”
Self-citationMutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in primary CNS lymphoma
Montesinos‐Rongen, M., Schmitz, R., Brunn, A., Gesk, S., Richter, J., Hong, K., Wiestler, O. D., Siebert, R., Küppers, R., & Deckert, M. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0709-7 · Cited by 112 · cited 4×
“These include gains in chromosome 18q21 being present in 37% of PCNSL and activating mutations of the CARD11 gene being present in 16% of PCNSL [5, 6].”
InfluentialSelf-citationPrimary diffuse large B‐cell lymphoma of the tonsil: Is a higher radiotherapy dose required?
Laskar, S. S., Bahl, G., Muckaden, M. A., Nair, R., Gupta, S., Bakshi, A. V., Gujral, S., Shet, T. M., Shrivastava, S. K., & Dinshaw, K. A. (2007) · Cancer · doi:10.1002/cncr.22841 · Cited by 101
Primary lymphoma of the central nervous system: just DLBCL or not?
Montesinos‐Rongen, M., Siebert, R., & Deckert, M. (2008) · Blood · doi:10.1182/blood-2008-04-149005 · Cited by 84 · cited 2×
“These include gains in chromosome 18q21 being present in 37% of PCNSL and activating mutations of the CARD11 gene being present in 16% of PCNSL [5, 6].”
Self-citationCourts, C., Montesinos‐Rongen, M., Martín-Subero, J. I., Brunn, A., Siemer, D., Zühlke‐Jenisch, R., Pels, H., Jürgens, A., Schlegel, U. S., Schmidt‐Wolf, I. G. H., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000248553.45456.96 · Cited by 51 · cited 2×
“While either the MYD88 L265P or the CARD11 mutation activates the NF-jB pathway, the combined presence of these mutations may act synergistically; thus, further enhancing NFjB activation [1, 5].”
Self-citation
Cited by
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Hunter, Z. R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R. J., Tripsas, C., Patterson, C. J., Sheehy, P., et al. (2014) · Blood · doi:10.1182/blood-2013-09-525808 · Cited by 488
Xu, L., Hunter, Z. R., Yang, G., Zhou, Y., Cao, Y., Liu, X., Morra, E., Trojani, A., Greco, A., Arcaini, L., et al. (2013) · Blood · doi:10.1182/blood-2012-09-454355 · Cited by 414
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W.-Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0613 · Cited by 409
Metadata
- Authors
- Montesinos-Rongen, M., Godlewska, E., Brunn, A., Wiestler, O. D., Siebert, R., & Deckert, M.
- Venue
- Acta Neuropathologica
- Published
- 2011-10-22
- Volume
- 122
- Issue
- 6
- Pages
- 791-792
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2072908214
- Cited by
- 178
- References
- 9
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.